Brought to you by 
AstraZeneca pays $2.5bn, plus earn-outs, for majority stake in Acerta Pharma
26 Aug 2020
Executive Summary
AstraZeneca PLC is further strengthening its blood cancer assets by acquiring a 55% stake in three-year-old private biopharma Acerta Pharma BV. Total consideration for the initial stake is $4bn, with $2.5bn payable up front and the remainder within the next three years.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Includes Earnout
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AstraZeneca pays $2.5bn, plus earn-outs, for majority stake in Acerta Pharma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice